Skip to main content

Market Overview

Dicerna Sells Oxlumo Royalty Interest To Royalty Pharma For $180M Upfront

Share:
Dicerna Sells Oxlumo Royalty Interest To Royalty Pharma For $180M Upfront
  • Royalty Pharma plc (NASDAQ: RPRXhas acquired Dicerna Pharmaceuticals Inc's (NASDAQ: DRNA) royalty interest in Oxlumo (lumasiran) for an upfront cash payment of $180 million and up to $60 million in contingent sales-based milestone payments.
  • The FDA and European Medicines Agency have approved Oxlumo (EMA) for the treatment of primary hyperoxaluria (PH) type 1 and is marketed by Alnylam Pharmaceuticals Inc (NASDAQ: ALNY).
  • Dicerna became entitled to royalties on worldwide net product sales of Oxlumo as part of a 2020 non-exclusive intellectual property cross-license agreement between Dicerna and Alnylam related to the companies' PH programs.
  • Dicerna is entitled to royalties in the mid to high single digits based on OXLUMO global net sales.
  • This transaction, together with Dicerna's cash, cash equivalents, held-to-maturity investments, and anticipated milestone and other payments from existing collaborations, is expected to extend Dicerna's projected cash runway and be sufficient to fund the execution of its current clinical and operating plan into 2024.
  • Price Action: DRNA shares closed 1.5% lower at $25.75 on Wednesday.
 

Related Articles (RPRX + DRNA)

View Comments and Join the Discussion!

Posted-In: Biotech M&A News Health Care Contracts Small Cap General

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com